Working… Menu

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04489940
Recruitment Status : Recruiting
First Posted : July 28, 2020
Last Update Posted : April 30, 2021
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
EMD Serono ( EMD Serono Research & Development Institute, Inc. )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 23, 2023
Estimated Study Completion Date : February 23, 2023